



IMAGION BIOSYSTEMS LIMITED

(ASX: IBX)

1 June 2023

Convertible Note Investment

MELBOURNE – Imagion Biosystems (ASX:IBX), a company dedicated to improving healthcare through the early detection of cancer, has received \$1,000,000 from Mercer Street Global Opportunity Fund, LLC, a US-based investment fund managed by Mercer Street Capital Partners, LLC (together, “Mercer”) pursuant to the convertible note agreement between the Company and Mercer announced on the ASX on 7 March 2023.

The Company will now proceed to issue 1,100,000 convertible notes with a face value of \$1 each, and 28,089,888 options in accordance with the terms of the convertible note agreement. Full details of these securities are set out in the Company's other ASX announcements dated 21 March 2023 and 1 June 2023.

The Company will use this funding to advance clinical development the Company's lead imaging agent as well as for other general working capital expenses.

-ENDS

About Imagion Biosystems

Imagion Biosystems is developing a new non-radioactive and precision diagnostic molecular imaging technology. Combining biotechnology and nanotechnology, the Company aims to detect cancer and other diseases earlier and with higher specificity than is currently possible.

For further information please visit www.imagionbiosystems.com

Authorisation & Additional information

This announcement was authorised by the Board of Directors of Imagion Biosystems Limited

U.S. Media Contact:

Casie Ost

Casie.ost@imagionbio.com

+1-619-693-4428

Australian Media & Investor Relations:

Hannah Howlett, WE Communications

We-AUImagionBiosystems@we-worldwide.com

+61 450 648 064

Imagion Biosystems Limited

ACN 616 305 027

Level 25, 525 Collins Street, Melbourne VIC 3000

www.imagionbiosystems.com